Rivaroxaban 2.5 MG [Xarelto]

DRUG3 trials

Sponsors

Maatschap Cardiologie Zwolle, University of Alberta, Assistance Publique - Hôpitaux de Paris

Conditions

Coronary Artery Disease (CAD)Left Ventricular ThrombusMyocardial Infarction, AcutePeripheral Arterial Disease (PAD)Type II Myocardial Infarction

Phase 2

Rivaroxaban in Type 2 Myocardial Infarctions

CompletedNCT04838808

University of AlbertaType II Myocardial Infarction

Start: 2021-04-05End: 2023-01-03Updated: 2023-03-27

Phase 3

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF

CompletedNCT05077683

Assistance Publique - Hôpitaux de ParisLeft Ventricular Thrombus, Myocardial Infarction, Acute

Start: 2021-10-10End: 2024-02-09Updated: 2024-07-10

Unknown Phase

Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk

CompletedNCT04753372

Maatschap Cardiologie ZwolleCoronary Artery Disease (CAD), Peripheral Arterial Disease (PAD)

Start: 2020-12-21End: 2023-09-13Updated: 2023-09-28

Related Papers

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.

2026-02-25

Rationale and design of the direct oral anticoagulants for prevention of left ventricular thrombus after anterior acute myocardial infarction (APERITIF) trial.

2023-09-142 citations

Anticoagulation in type 2 myocardial infarctions: Lessons learned from the rivaroxaban in type 2 myocardial infarctions feasibility trial.

2023-04-221 citations